Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 30, 2025 07:00 ET | Source: AC Immune SA

AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update

AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update Continuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative...
April 29, 2025 07:57 ET | Source: ZyVersa Therapeutics

ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson’s Disease

ZyVersa's IC 100 blocked microglial NLRP1 inflammasome activation and reduced alpha-synuclein accumulation supporting its potential for Parkinson's Disease
March 25, 2025 07:00 ET | Source: AC Immune SA

AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025

AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 AC Immune to host symposium highlighting the company’s industry-leading pipeline of active...
November 14, 2024 07:00 ET | Source: AC Immune SA

AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein...
February 22, 2024 07:00 ET | Source: AC Immune SA

AC Immune Announces Upcoming Presentations at AD/PD™ 2024

AC Immune Announces Upcoming Presentations at AD/PD™ 2024 Multiple presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024)Andrea Pfeifer, Ph.D., CEO to...
October 27, 2022 07:00 ET | Source: Amydis, Inc.

Amydis Awarded Third Grant From The Michael J. Fox Foundation To Support First-In-Human Study of a Retinal Tracer for Parkinson’s Disease

SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Amydis Inc., a privately held clinical-stage company pioneering a platform of diagnostic drug candidates targeting molecular biomarkers in the eye, today...
January 27, 2022 09:00 ET | Source: Enterin Inc.

Enterin Meets Study Endpoints for the Phase 2b (KARMET) Study Involving Patients With Parkinson's Disease

PHILADELPHIA, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and...
January 25, 2022 09:00 ET | Source: Enterin Inc.

Enterin to Announce Top-Line Results From the Phase 2b Study for Parkinson's Disease

PHILADELPHIA, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and...
January 11, 2022 15:00 ET | Source: Enterin Inc.

Enterin and Their Collaborators at NIH Announce That Alpha-Synuclein, the Culprit in Parkinson's Disease, is Core and Central to Normal Immune Function

PHILADELPHIA, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and...
January 10, 2022 09:00 ET | Source: Enterin Inc.

Enterin Announces Appointment of Dr. Patrik Brundin to Its Scientific Advisory Board

PHILADELPHIA, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and...

Next Page keyboard_arrow_right